Aurobindo Pharma shares at day’s high despite arm’s unit getting form 483 from USFDA

Last week, the US drug regulator had issued another Form 483 with three observations to Aurobindo Pharma after inspecting its Unit-V, an active pharmaceutical ingredient (API) manufacturing facility of its wholly-owned subsidiary Apitoria Pharma Pvt. Ltd., in Telangana.